Biotech

Hollis-Eden Namesake Fired 'For Cause'

Stock quotes in this article:HEPH 

Hollis-Eden Pharmaceuticals'(HEPH) founder and Chief Executive Richard Hollis was fired "for cause" by his board last week, triggering a clause in his employment contract that strips him of millions of dollars in severance payments.

Hollis's termination as CEO of the San Diego-based drug company that bears his name was effective March 18 but disclosed publicly Monday night in a filing with the Securities and Exchange Commission.

The departure of a drug or biotech company CEO is a fairly common event, especially in the current troubled economic environment. Yet, these management changes are typically performed with a certain amount of public discretion that allows the executive to depart with his reputation intact and his financial nest egg bolstered with a generous severance package.

Last week's firing of Hollis, however, wasn't very demure. The 8-K filing Monday states that a special committee of Hollis-Eden's board, made up of non-employee directors, terminated Hollis "pursuant to Section 4.3 of his employment agreement."

Monday's disclosure doesn't include any details about Section 4.3 of Hollis's employment agreement, but a quick search through SEC filings reveals that this particular section of Hollis's contract defines various conditions under which he could be fired "for cause."

These conditions include being in material breach of his employment contract; participating in any activity or engaging in behavior that is competitive or injurious to the company; committing fraud against the company; stealing company funds or property for his personal use; or conviction of "any crime involving dishonesty or moral turpitude," according to Hollis's employment agreement that is included in the company's proxy statements filed with the SEC.

TheStreet Premium Services

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
Dow Jones S&P 500 NASDAQ 10-Year Note
12,393.45 1,310.33 2,827.34 15.81
Oil *
101.78
DOWN
26.41
DOWN
2.99
DOWN
10.02
DOWN
0.44
10 Yr
1.58%
SPDR Gold
151.62
-0.21%
-0.23%
-0.35%
-2.71%
Data delayed 20 minutes

Top Stories and Tools

Articles From

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet